New triple therapy targets Hard-to-Treat cancers

NCT ID NCT04708470

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of three drugs—bintrafusp alfa, PDS01ADC, and entinostat—in adults with advanced HPV-related cancers (like cervical, anal, or throat cancer) or certain colon cancers that haven't responded to standard treatment. The goal is to find a safe dose and see if the combo can shrink tumors. Participants receive treatment for up to 2 years and are followed for safety and response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bintrafusp alfa, PDS01ADC, and entinostat
What this could lead to
If it works, this could offer a new treatment option for advanced HPV-related and certain colon cancers that are hard to treat.
What could go wrong
This is an early phase I/II trial with only 55 participants, so results may not apply to everyone. The drugs can cause side effects, and the combination may not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.